Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Prana Biotechnology 2018 AGM Presentation

November 16, 2018August 16, 2022 Alterity Therapeutics

2018_11_16 AGM Presentation 2018

2018

Post navigation

Prana AGM Investor Conference Call

Life Biosciences LLC leads strategic investment of up to A$44.5 million in Prana

Related Posts

HCW&Co publishes Prana Reach2HD trial report, results “beat expectations”

February 24, 2014August 16, 2022

XBRL 30 June 2022 filed with the SEC

September 1, 2022October 26, 2022

Prana Announces that PBT2 Reduces Cognitive Impairment Caused by Tau Protein Accumulation

July 17, 2013August 16, 2022

Recent Posts

Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer’s Disease
ShareCafe Investor Webinar Recording
ShareCafe Investor Webinar Presentation
Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065